Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1314-1318

  Takeshima, Fuminao ^a   Matsumura, Masato ^b   Makiyama, Kazuya ^c   Ohba, Kazuo ^d   Yamakawa, Masaki ^e   Nishiyama, Hitoshi ^f   Yamao, Takuji ^g   Akazawa, Yuko ^a   Yamaguchi, Naoyuki ^a   Ohnita, Ken ^a   Ichikawa, Tatsuki ^a   Isomoto, Hajime ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Department of Gastroenterology and Hepatology Matsumura Clinic   (Japan)

^c Shunkaikai Inoue Hospital   (Japan)

^d Isahaya Health Insurance General Hospital   (Japan)

^e Nagasaki Municipal Medical Center   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^g Sasebo Shiritsu Sogo Hospital   (Japan)

Author keywords

Colitis, ulcerative prevention Control; Colitis, ulcerative therapy; Mesalamine administration Dosage

Indexed keywords

MESALAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER DYSFUNCTION; LONG TERM CARE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; ULCERATIVE COLITIS; CLINICAL TRIAL; COLITIS, ULCERATIVE; DOSE RESPONSE; JAPAN; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDY; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

COHORT STUDIES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MESALAMINE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905121113     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890567     Document Type: Article

References (18)

1. Travis SP, Stange EF, Lemann M et al: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis, 2008; 2: 24-62
2. Ford AC, Achkar JP, Khan KJ et al: Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol, 2011; 106: 601-16
3. Ham M, Moss AC: Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol, 2012; 5: 113-23
4. Hanauer SB: High-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther, 2006; 24(Suppl.3): 37-40
5. Paoluzi OA, Iacopini F, Pica R et al: Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther, 2005; 21: 1111-19
6. Fockens P, Mulder CJ, Tytgat GN et al: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol, 1995; 7: 1025-30
7. Miner P, Hanauer S, Robinson M et al: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci, 1995; 40: 296-304
8. Mulder CJ, Tytgat GN, Weterman IT et al: Double -blind comparison of slowrelease 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology, 1988; 95: 1449-53
9. Prantera C, Kohn A, Campieri M et al: Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther, 2009; 30: 908-18
10. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 1987; 317: 1625-29
11. Research Group for Intractable Inflammatory Bowel Disease, The Annual Report for 2011, the Ministry of Health and Welfare, Japan
12. Hiwatashi N, Suzuki Y, Mitsuyama K et al: Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol, 2011; 46: 46-56
13. Watanabe M, Hanai H, Nishino H et al: Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double- blind, double-dummy, randomized multicenter study. Inflamm Bowel Dis, 2013; 19: 1681-90
14. Sutherland L, Macdonald JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2006: CD000544
15. Naganuma M, Iwao Y, Ogata H et al: Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis, 2001; 7: 221-25
16. Frieri G, Pimpo MT, Andreoli A et al: Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. Aliment Pharmacol Ther, 1999; 13: 577-82
17. Khan N, Abbas AM, Koleva YN, Bazzano LA: Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis, 2013; 19: 1123-29
18. Travis SP, Tysk C, de Silva HJ et al: Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut, 1994; 35: 1282-86